Eli Lilly and Company

05/13/2022 | Press release | Distributed by Public on 05/13/2022 16:02

FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes